Diagnostic role of plasma ORM2 in differentiating prostate cancer from benign prostatic hyperplasia.
Yuqiu GeBin XuHongzhou CaiWentao JingQiong OuyangQinbo YuanXu LiYuanming FanYang ShenQianqian ShiQiangdong WangLi CuiXiaojian YinGaoxiang MaPublished in: Journal of cancer research and clinical oncology (2022)
In summary, our study suggests that ORM2 could be treated as a complementary biomarker for PSA in distinguishing PCa from BPH.